Ishita Drugs Industries Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Ishita Drugs & Industries Ltd is ₹ 81.93 as of 06 May 15:30 . The P/E Ratio of Ishita Drugs & Industries Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Ishita Drugs & Industries Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Ishita Drugs & Industries Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Ishita Drugs & Industries Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Ishita Drugs & Industries Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Ishita Drugs & Industries Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Ishita Drugs & Industries Ltd

Ishita Drugs & Industries Limited was incorporated in February, 1992 by Jagdish Agarwal.
The Company is engaged in the manufacture of various Activa Pharma Ingredients, drug intermediates, fine chemicals and excipient.
The company supplies its products to leading pharmaceutical companies of India.
The products are also being exported to various countries across the world.
The plant has been designed and constructed to meet GMP norms. The genesis of the Ishita Group in 1992 was the result of the entrepreneurial spirit of Mr. Jagdish Agrawal, who set up a reactive dye manufacturing unit in Ahmedabad.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Ishita Drugs & Industries Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Ishita Drugs & Industries Ltd or Sanofi India Ltd?

Market cap of Ishita Drugs & Industries Ltd is 24 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Ishita Drugs & Industries Ltd and Sanofi India Ltd?

The stock performance of Ishita Drugs & Industries Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ishita Drugs & Industries Ltd and Sanofi India Ltd?

As of May 6, 2026, the Ishita Drugs & Industries Ltd stock price is INR ₹81.93. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Ishita Drugs & Industries Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Ishita Drugs & Industries Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.